Moreover, as GLP-1 is considered a therapeutic target for obesity and diabetics in human clinics, the mechanism underlying increased serum GLP-1 concentration in ABX-treated rats warrants further investigation. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.